Jill Andersen Sells 34,939 Shares of Invivyd (NASDAQ:IVVD) Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Jill Andersen sold 34,939 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $1.58, for a total value of $55,203.62. Following the sale, the insider owned 181,736 shares of the company’s stock, valued at approximately $287,142.88. This represents a 16.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jill Andersen also recently made the following trade(s):

• On Tuesday, February 17th, Jill Andersen sold 32,771 shares of Invivyd stock. The stock was sold at an average price of $1.54, for a total value of $50,467.34.

Invivyd Price Performance

Shares of NASDAQ IVVD opened at $1.61 on Friday. Invivyd, Inc. has a 1-year low of $0.46 and a 1-year high of $3.07. The business has a fifty day moving average price of $2.17 and a 200 day moving average price of $1.75. The stock has a market capitalization of $375.32 million, a P/E ratio of -3.43 and a beta of 0.60.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Courier Capital LLC acquired a new stake in shares of Invivyd during the fourth quarter worth about $25,000. Bronte Capital Management Pty Ltd. acquired a new stake in Invivyd during the 4th quarter valued at approximately $27,000. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Invivyd in the 2nd quarter valued at $27,000. DRW Securities LLC purchased a new stake in shares of Invivyd in the 4th quarter valued at $27,000. Finally, Vanguard Personalized Indexing Management LLC increased its stake in shares of Invivyd by 238.6% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after acquiring an additional 28,146 shares during the period. 70.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on IVVD shares. D. Boral Capital reissued a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. BTIG Research reissued a “buy” rating on shares of Invivyd in a research report on Wednesday, January 21st. HC Wainwright boosted their target price on Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Invivyd in a research note on Monday, December 29th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Invivyd presently has an average rating of “Hold” and an average target price of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.